MRK stock forecast, quote, news & analysis

Key Takeaways

• MRK shares closed at $130.20 on July 31, 2026, rising approximately 3.9% over the trailing 30-day period from the July 1 close of $125.37.
• Multiple Wall Street analysts raised price targets in recent weeks, with firms including Guggenheim ($145), Wells Fargo ($150), Scotiabank ($155), and BMO Capital ($142) maintaining bullish ratings ahead of the Q2 2026 earnings report.
• The launch of Keytruda Qlex, the subcutaneous formulation of Merck's flagship oncology drug, gained momentum following the April 2026 implementation of a permanent J-code, improving physician reimbursement confidence.
• Merck is actively pursuing pipeline diversification through acquisitions — including Terns Pharmaceuticals and Cidara Therapeutics in 2026 — to offset the approaching 2028 Keytruda patent cliff.
• Generic erosion from Januvia/Janumet and Bridion is expected to create an estimated $2.5 billion revenue headwind in 2026, partially offset by growth from Winrevair, Capvaxive, and Welireg.

Current Market Snapshot

Merck & Co. shares have demonstrated measured resilience through mid-2026, trading above both the 50-day and 200-day simple moving averages since mid-June. The stock closed at $130.20 on the final trading day of July, reflecting a 3.9% gain over the preceding 30 days and a robust 16% advance since early May, when shares traded near $112. Investor sentiment has been supported by a wave of analyst price-target increases, positive early signals from the Keytruda Qlex subcutaneous rollout, and steady progress across Merck's expanding late-stage pipeline. The broader pharmaceutical sector has also benefited from favorable fund flows into biotech and pharma equities, contributing to a constructive backdrop for large-cap names. Merck's Q2 2026 earnings call, scheduled for August 4, is widely anticipated as a near-term catalyst for further clarity on product trajectories and pipeline timelines.

Merck & Co. (MRK) Business Overview and Competitive Position

Merck & Co., Inc. is one of the world's largest research-intensive biopharmaceutical companies, headquartered in Rahway, New Jersey. The company develops and markets prescription medicines, vaccines, biologic therapies, and animal health products across oncology, infectious diseases, cardiovascular, immunology, and respiratory therapeutic areas. Keytruda, Merck's PD-1 inhibitor, remains the cornerstone of its pharmaceutical portfolio, generating approximately $31.7 billion in 2025 revenue and accounting for roughly half of the company's total sales. The drug holds 44 FDA-approved indications across 19 tumor types. Beyond oncology, Merck's vaccine franchise — including the 21-valent pneumococcal conjugate vaccine Capvaxive — its pulmonary arterial hypertension therapy Winrevair, and its animal health division provide meaningful diversification. With a market capitalization of approximately $320 billion, Merck ranks among the largest pure-play pharmaceutical companies globally. The company has publicly committed to launching 20 new drugs by 2030 as it prepares for the 2028 U.S. patent expiration of Keytruda.

Recent Developments Driving MRK

Several meaningful developments have shaped Merck's investment narrative in recent weeks. The launch of Keytruda Qlex — a subcutaneous version of Keytruda administered in minutes rather than hours — gained traction following the permanent J-code implementation on April 1, 2026. BMO Capital raised its Q2 2026 Keytruda Qlex estimate to $363 million, above the consensus of $334 million, citing improved reimbursement visibility for physicians. On the regulatory front, the FDA granted expanded approval for Capvaxive to include children and adolescents aged 2 through 17, broadening the vaccine's addressable market. Merck's HIV portfolio also advanced with the April 2026 FDA approval of IDVYNSO, a once-daily single-tablet regimen, followed by an access agreement with the ADAP Crisis Task Force.

On the corporate strategy front, Merck continued its acquisition-driven pipeline expansion, agreeing to acquire Terns Pharmaceuticals to bring TERN-701 — a chronic myeloid leukemia therapy — into its portfolio. The company also announced plans to reorganize its healthcare business into separate oncology and non-oncology units, widely interpreted as a strategic move to insulate diversified assets ahead of the Keytruda patent cliff. However, headwinds persist: Bridion lost U.S. patent exclusivity in July 2026, and generic competition for Januvia/Janumet continues to pressure diabetes franchise revenues. Additionally, U.S. lawmakers opened a national security investigation into Merck's clinical trial operations in China, introducing a geopolitical risk factor that investors are monitoring closely.

Trending AI Robots

For traders seeking an automated approach to navigating stocks like Merck, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots currently active in the market. Tickeron hosts hundreds of AI-powered trading bots covering thousands of tickers across equities, ETFs, and forex, but only the highest-performing and most relevant bots appear in the trending section. Each bot operates with a distinct strategy, timeframe, and risk profile — ranging from short-term swing trading to longer-term position-based approaches — allowing traders to evaluate performance metrics and trading histories before making decisions. The page is regularly refreshed to reflect real-time market dynamics and bot performance rankings. Exploring the Trending AI Robots section can help traders identify data-driven strategies aligned with current market conditions.

2026 Outlook and What Investors Should Watch

Looking ahead, Merck's Q2 2026 earnings report on August 4 represents the most immediate focal point for investors. Key metrics to watch include Keytruda Qlex conversion rates, Winrevair sales progression, and Capvaxive vaccine uptake. Guggenheim projects Q2 revenue of $16.25 billion with EPS of $0.28, while full-year 2026 estimates stand at approximately $66.4 billion in revenue and $5.19 in earnings per share. Beyond quarterly results, investors should monitor upcoming clinical data readouts for late-stage pipeline assets including sac-TMT, tulisokibart for ulcerative colitis, and MK-3000. The pace of Keytruda Qlex adoption — both in the U.S. and in early ex-U.S. markets — will be critical for gauging how effectively Merck can extend Keytruda's commercial runway toward 2028. Generic headwinds from Bridion, Januvia, and Janumet will continue pressuring top-line growth, while the integration of newly acquired assets and pipeline execution will shape long-term sentiment. Broader macroeconomic factors, including potential changes to Medicare drug price negotiation rules and ongoing U.S.-China policy tensions affecting clinical trial operations, also warrant attention as 2026 progresses.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations